Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

ClinicalTrials.gov ID: NCT04076462

Public ClinicalTrials.gov record NCT04076462. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

Study identification

NCT ID
NCT04076462
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Camurus AB
Industry
Enrollment
72 participants

Conditions and interventions

Conditions

Interventions

  • CAM2029 (octreotide subcutaneous depot) Drug
  • Matching placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 18, 2019
Primary completion
May 1, 2023
Completion
May 1, 2023
Last update posted
Apr 24, 2024

2019 – 2023

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
UCLA Department of Medicine Division of Endocrinology Los Angeles California 90095
Stanford University Medical Center Palo Alto California 94305
Prufen Clinical Research LLC Miami Florida 33130
University of Michigan Ann Arbor Michigan 48106
Mayo Clinic Rochester Minnesota 55905
Washington University in St. Louis, School of Medicine St Louis Missouri 63110
Palm Research Center Las Vegas Nevada 89148
Columbia University Medical Center New York New York 10018
University of Cincinnati Cincinnati Ohio 45267
Thomas Jefferson University Philadelphia Pennsylvania 19107
Allegheny Endocrinology Associates Pittsburgh Pennsylvania 15212
Research Institute of Dallas Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04076462, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04076462 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →